Skip to Main Content

Submit your questions by Friday, Nov. 1

The full Q&A will be published Tuesday, Nov. 12

Dr. David Liu, a researcher at the Broad Institute of MIT and Harvard, is among the lead inventors of “prime editing,” a new form of the genome-editing tool CRISPR-Cas9 that has the potential to correct almost all disease-causing DNA glitches. You can read the full story here. The technology has generated significant enthusiasm in the scientific community, and also prompted questions.

Submit your questions for Dr. Liu through the form below by Friday, Nov. 1. He will answer as many as he can in an exclusive Q&A for STAT Plus subscribers. You will receive an email notification when his answers have been published on Nov. 12.

About the speaker

David R. Liu is the Richard Merkin Professor, director of the Merkin Institute of Transformative Technologies in Healthcare, and vice chair of the faculty at the Broad Institute of  MIT and Harvard; a professor of chemistry and chemical biology at Harvard University and a Howard Hughes Medical Institute (HHMI) investigator. Liu’s research includes the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential; and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries.